Long-acting naltrexone implant to help prevent opioid relapse
Part of Mental health clinical trials.
This Phase 2 study tests whether a long-acting naltrexone implant can help people with opioid use disorder stay away from opioid relapse. You may get the implant after safely finishing opioid withdrawal and stopping other naltrexone dosing at the right time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 65 years old and able to speak and understand English well enough for study visits
- Have a current diagnosis of opioid use disorder (OUD) within the last 12 months and want relapse-prevention treatment
- Finish opioid withdrawal and pass a medicine test showing you can tolerate naloxone
- Be medically and mentally able to safely get either naltrexone or the study implant, based on screening checks
- Be willing and able to get a small implant placement procedure in the abdomen using local numbing medicine
- Have body weight or BMI in the allowed range, and if you can get pregnant, agree to effective birth control and pregnancy testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two forms of naltrexone (a medication used for alcohol and opioid dependence) in healthy volunteers. It tests how well the body processes and tolerates a low or high-dose implant versus the standard monthly injection.
This trial tests whether a combination of buprenorphine (through your care plan) and a monthly extended-release naltrexone (XR-NTX) shot can help prevent opioid relapse. It may help people who are ready to move toward a naltrexone-based relapse-prevention treatment after detox.
This study tests a faster way to start buprenorphine (a medication for opioid use disorder) by using naloxone to briefly trigger mild withdrawal. This could help people get started on treatment more comfortably and quickly.
This trial compares taking buprenorphine by mouth versus as an injection for opioid use disorder. It aims to see which option helps people stay on treatment and reduces opioid use over about a year.
This trial tests whether starting buprenorphine using a low-dose plan is a safe and workable way to treat opioid use disorder. You may be able to join if you are 18+, have opioid use disorder, and can follow the study medication and visits.
This Phase 2 study looks at what opioid withdrawal looks like in the body and whether they can measure it in a meaningful way. You may join if you have an opioid use disorder, can show physical dependence, and are interested in tapering (gradually reducing) opioids under study care.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.